Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Tag Archives for " Antineoplaston "
Revlimid, Ninlaro, Dexamethasone (IRd) vs. Antineoplastons- Multiple Myeloma
“Among the (MM) patients not proceeding to SCT, AEs led to dose reductions in 27 (64%) patients, of whom 9 (21%), 19 (45%), and 16 (38%) required Revlimid, Ninlaro and Dexamethasone dose reductions” Hi
Continue reading